At the end of November, we had the pleasure of welcoming Dr. Bárbara Mora-Lagos, Assistant Professor at Universidad Autónoma de Chile, to the Cancer Cell Biology Research Group. During her three-week stay, she shared her expertise on chemoresistance in gastric cancer and genomics, fostering enriching scientific discussions and exchange of knowledge. This collaboration not only[…]
On 8-10 October 2025, we attended the 20th ASEICA International Congress, which took place in Bilbao, Spain. We took advantage of the networking opportunities this congress offers, as well as to learn about the research that is being conducted by other groups in Spain and share our work with them.
Agència de Gestió d’Ajuts Universitaris i Recerca (AGAUR) awarded our lab member Mireia Peláez Muñoz a FI-STEP fellowship, which will allow her to pursue her Ph.D. studies in our research group, under the supervision of Dr. Soto-Cerrato, focusing on the identification of vulnerabilities and biomarkers related to drug-tolerant persister cells in lung cancer patients for[…]
Our PhD student since 2023 and FI-fellow, Ana Aurora Torres, has been awarded an FPU fellowship by the Spanish Ministry of Science, Innovation and Universities. This grant will allow her to continue her thesis project on evaluating the inhibition of cytoprotective autophagy as a new therapeutic approach to overcome resistance to conventional treatments in lung[…]
Our recently published research paper, “Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies”, led by Dr. Vanessa Soto-Cerrato, focuses on the identification and validation of a novel specific, directly binding survivin inhibitor for cancer treatment and tumor sensitization to conventional proapoptotic treatments. Asenapine[…]
The Cancer Cell Biology Research Group has just published a research article in Biochemical Pharmacology journal titled “Deregulation of lactate permeability using a small-molecule transporter (Lactrans-1) disturbs intracellular pH and triggers cancer cell death” led by Dr. Ricardo Pérez-Tomás and Dr. Roberto Quesada. In this study, we explored the anticancer potential of a new strategy[…]
We are glad to start this academic year by confirming our attendance to ONCOBELL 3rd International Symposium and the 36th EORTC-NCI-AACR Symposium, which will take place in Barcelona, on 3-4 and 23-25 October 2024, respectively.
The Annual Congress of the European Association for Cancer Research (EACR) will take place in Torino, Italy, on 12-15 June 2023. We are very excited to be in attendance and to have the opportunity to expand our knowledge!
Dr. Laura Devis-Jauregui has recently joined the Cancer Cell Biology Research Group as a Ramón y Cajal Investigator at the University of Barcelona. During her postdoctoral fellowship with Dr. David Llobet-Navàs (2018-2022), she deepened her expertise in endometrial cancer by using patient-derived orthotopic xenografts (PDOX), CRISPR screening technologies, and contributed to multiple projects focused on[…]
You can find the research paper “Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma” led by Dr. Vanessa Soto-Cerrato and Dr. Ricardo Pérez-Tomás, now published in Pharmaceutics journal. In this work, we analyze the antimetastatic properties of prodigiosin and obatoclax (GX15-070), anticancer drugs of the Prodiginines (PGs) family. We studied PGs’ effects[…]